Human respiratory syncytial virus (RSV) is a ubiquitous pathogen that infects everyone
worldwide early in life and is a leading cause of severe lower respiratory tract disease in the …

Vaccine development, which began with Edward Jenner's observations in the late 18th
century, has entered its 4th century. From its beginnings, with the use of whole organisms …

Small animal models are needed in order to evaluate the efficacy of candidate vaccines and
antivirals directed against the severe acute respiratory syndrome coronavirus (SARS CoV) …

We investigated the contributions of the structural proteins of severe acute respiratory
syndrome (SARS) coronavirus (CoV) to protective immunity by expressing them individually …

Nipah virus, a member of the paramyxovirus family, was first isolated and identified in 1999
when the virus crossed the species barrier from fruit bats to pigs and then infected humans …

Infection of infants in their first year of life, children and elderly people with the respiratory
syncytial virus (RSV) endangers the life of the patient. An attempt to develop a formalin …

Live-attenuated respiratory syncytial virus (RSV) vaccines offer several advantages for
immunization of infants and young children:(1) they do not cause vaccine-associated …

Asthma is a common and debilitating disease that has substantially increased in prevalence
in Western Societies in the last 2 decades. Respiratory tract infections by respiratory …

In children under 5 years of age, human parainfluenza viruses (HPIVs) as a group are the
second most common etiology of acute respiratory illness leading to hospitalization …

Paramyxoviruses such as human parainfluenza viruses that bear inserts encoding protective
antigens of heterologous viruses can induce an effective immunity against the heterologous …